Journal of Hepatology
Volume 48, Issue 5 , Pages 714-720 , May 2008

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B

  • Chee-Kin Hui

      Affiliations

    • Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    • Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
    • State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China
    • ,
  • Hai-Ying Zhang

      Affiliations

    • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    • ,
  • Scott Bowden

      Affiliations

    • Victorian Infectious Diseases Reference Laboratory, Vic., Australia
    • ,
  • Stephen Locarnini

      Affiliations

    • Victorian Infectious Diseases Reference Laboratory, Vic., Australia
    • ,
  • John M. Luk

      Affiliations

    • Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    • ,
  • Kar-Wai Leung

      Affiliations

    • Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    • Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
    • State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China
    • ,
  • Yui-Hung Yueng

      Affiliations

    • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    • ,
  • April Wong

      Affiliations

    • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    • ,
  • Frank Rousseau

      Affiliations

    • Gilead Sciences Inc., Durham, NC, USA
    • ,
  • Kwok-Yung Yuen

      Affiliations

    • Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    • Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
    • State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China
    • ,
  • Nikolai N. Naoumov

      Affiliations

    • Institute of Hepatology, University College London, London, UK
    • ,
  • George K.K. Lau

      Affiliations

    • Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
    • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    • Corresponding Author InformationCorresponding author. Tel.: +852 28184300; fax: +852 28184030.

Received 23 July 2007 ,Revised 8 October 2007 ,Accepted 11 October 2007.

References 

  1. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38:S18–S23
  2. Mast EE, Alter MJ. Epidemiology of hepatitis B virus: an overview. Sem Virol. 1993;4:273–283
  3. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174
  4. Yu WM, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265–272
  5. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64:51–68
  6. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;39:S3–S25.
  7. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian–Pacific consensus update working party on chronic hepatitis B. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–489
  8. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  9. Lok AS. The maze of treatments for hepatitis B. N Eng J Med. 2005;352:2743–2746
  10. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37:748–755
  11. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806
  12. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273
  13. Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther. 2007;12:705–718
  14. Ishak KG, Baptista A, Bianchi L, Callea F, De Groote J, Gudak F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  15. Colgrove R, Japour A. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden and the implications of multiple drug HIV therapy for the evolution of antiviral resistance. Antiviral Res. 1999;41:45–56
  16. Clumeck N, De Wit S. Update on highly active antiretroviral therapy: progress and strategies. Biomed Pharmacother. 2000;54:7–12
  17. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997;26:216–225
  18. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine and adefovir. Antimicrob Agents Chemother. 2000;44:551–560
  19. Lau GK, Tsiang M, Hou JL, Yuen ST, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese patients: a viral dynamics study. Hepatology. 2000;32:394–399
  20. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–962
  21. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758
  22. Hui CK, Bowden S, Jackson K, Au WY, Fong DT, Lie AKW, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood. 2005;105:2616–2618
  23. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapta I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 2003;39:595–605
  24. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:1527–1532
  25. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68
  26. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo R, et al. A randomized double blind phase II study of lamivudine compared with lamivudine plus adefovir dipivoxil for treatment naı¨ve patients with chronic hepatitis B: week 52 analysis. J Hepatol. 2003;38:25–26
  27. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen positive chronic hepatitis B. Gastroenterology. 2005;129:528–536
  28. Lim SG, Ng TM, Kung N, Krastev Z, Volfana M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49–56
  29. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Eng J Med. 2005;352:2682–2695
  30. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217
  31. Marcellin P, Chang T, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  32. Hadziyannis S, Tassopoulos N, Heathcote E, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807
  33. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol. 2005;42:17
  34. Lampertico P, Marzano A, Levrero M, Santantonio T, Andreone P, Brunetto M, et al. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 650 patients. J Hepatol. 2006;44:S51

☆ F.R. is an employee of Gilead Sciences. The authors who have taken part in the research of this paper declared that they received grants from Gilead Sciences. GKK Lau received a grant from Gilead Science and RGC Grant HKU 7679/06M to carry out this study.

PII: S0168-8278(07)00653-8

doi: 10.1016/j.jhep.2007.10.013

Journal of Hepatology
Volume 48, Issue 5 , Pages 714-720 , May 2008

Article Tools

* Image Usage & Resolution